Archive | .

A Dynamic Agenda Presented by the Society of Urologic Oncology

November 29 – December 1, 2017, Washington, DC

Jose A. Karam, MD, FACS Associate Professor Department of Urology, Division of Surgery The University of Texas MD Anderson Cancer Center Houston, Texas   The 18th annual meeting of the Society of Urologic Oncology presented an agenda covering a broad spectrum of topics in genitourinary cancers, including a significant amount of emerging data on renal […]

Continue Reading 0

­­Frontline Strategies in RCC:
Capturing Pivotal New Data, Optimizing Treatment Options

        Editor’s note: This report by the Kidney Cancer Journal integrates recently published peer-reviewed medical literature and results presented at two meetings, the European Society of Medical Oncology (ESMO) sessions and the Society for Immunotherapy of Cancer (SITC) meeting, both held in late 2017. The content, compiled independently by the journal, was […]

Continue Reading 0

Mobile Health Applications in Patients
With Metastatic Renal Cell Carcinoma

Introduction During the last decade, 10 drugs have been approved by the Food and Drug Administration (FDA) for the treatment of metastatic renal cell carcinoma (mRCC). Many of these treatments are oral tyrosine kinase inhibitors (TKI’s) targeting the vascular endothelial growth factor (VEGF) receptor. These TKI’s are known to cause a variety of side effects […]

Continue Reading 0